Fig. 1From: Preclinical development of a long-acting trivalent bispecific nanobody targeting IL-5 for the treatment of eosinophilic asthmaSchematic depicting the immunization and screening strategy used to isolate IL-5 Nbs. PBLs, peripheral blood lymphocytes. The cropping gel of purified IL-5-Fc antigen is displayedBack to article page